Genmab — Juni 2019
-
tak for dine indputs sukker. Men selv i det tilfælde de misser de 2 store salgs milestones i år (den på 2,5 mia burde være tæt på 99% sikker) så har de jo stadig maaaaaser af likvider i nkassen. Det er ikke sådan de står og kigger ned i dybet
-
Selv hvis de vælger at tage de 2 stoffer et skridt videre selv, så kommer det stadig ikke til at koste over 2 mia frem til og med 2021. Og i den samme periode vil dara stadig stige hvorfor kassen vil blive stadig størrer
-
But link to this poster where the truble perhaps are mentioned https://media4.asco.org/239/13730/178038/178038_poster_big_1.jpg
-
Hvornår får vi nyt fra Tisotumab and Enapotamab
-
@E.L Guess what is in on Monday
-
Then as it relates to DR5/5 HexaBody and the CD3xCD20 DuoBody programs, we're doing dose escalation for both and it's going well, I can tell you for both programs. And when we think about potentially partnering either one of these programs, I think there's a good chance that we need a partner because the market could potentially be huge for a program like the DR5/DR5 HexaBody program.
-
It's a well-validated target preclinically, and we have seen some very encouraging signs of early activity already with only a handful of patients already reflected up at the Capital Markets Day last September. So we would definitely expect that we need a partner for that program to maximize the potential of that program if we see good signs of clinical efficacy with our HexaBody product.
-DR5/DR5 (GEN1029) og DuoBody
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind